Upon completion, this project will determine if treatment of metabolic acidosis in non-diabetic study participants with reduced kidney function (chronic kidney disease \[CKD\] stage 3) associated with high blood pressure (hypertension) and macroalbuminuria, the latter indicating pronounced kidney injury, using either base-producing fruits and vegetables (F+V) or standard therapy for treatment of metabolic acidosis with the medication sodium bicarbonate (NaHCO3) 1) slows progression of CKD toward end-stage renal disease \[ESRD\]; 2) improves indices of cardiovascular disease (CVD) risk; and 3) better preserves plasma acid-base parameters. These studies are designed to compare the differential effects of treating the metabolic acidosis of CKD with F+Vs or NaHCO3 on kidney outcomes, including progression to ESRD, on indices of CVD risk and on plasma acid-base parameters.
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Difference in estimated glomerular filtration rate (eGFR) at follow up
Timeframe: eGFR will be measured at baseline and yearly for 10 years
Difference in the rate of eGFR change during follow up
Timeframe: eGFR rate of change will be measured at 3, 5, and 10 years
Difference in the net eGFR change during follow up
Timeframe: eGFR net change compared to baseline will be measured at 3, 5, and 10 years
Difference in the number of participants who reach need for kidney replacement therapy (KRT)
Timeframe: Number of participants reaching KRT will be determined at years 3, 5, and 10 from baseline
Difference in change in urine albumin excretion during follow up
Timeframe: UACR will be measured at baseline and yearly for 10 years
Difference in change in urine N-acetyl-D -glucosaminidase (UNAG) excretion during follow up
Timeframe: UNAG will be measured at baseline and yearly for 10 years
Difference in change in urine angiotensinogen (UATG) excretion during follow up
Timeframe: UATG will be measured at baseline and yearly for 10 years